Table 1 Study population characteristics.
Total | N = 539 |
|---|---|
Patients | |
Age – years, median (range) | 63 (17–87) |
Sex – Male, n (%) | 335 (62.1) |
Treatment center, n (%) | |
Lyon & St Etienne | 327 (60.7) |
Lille | 183 (34.0) |
Caen | 29 (5.4) |
Histology, n (%) | |
DLBCL NOS | 284 (52.7) |
GC | 37 (6.9) |
ABC | 38 (7.1) |
Not specified | 209 (38.8) |
Transformed indolent B-cell lymphoma | 98 (18.1) |
Mantle cell lymphoma | 30 (5.6) |
Follicular/marginal zone lymphoma | 66 (12.3) |
Primary mediastinal B-cell lymphoma | 20 (3.7) |
Richter transformation | 18 (3.3) |
Others | 23 (4.3) |
CAR T cell used, n (%) | |
Axi-cel | 319 (59.2) |
Brexu-cel | 30 (5.6) |
Tisa-cel | 144 (26.6) |
Liso-cel | 43 (8.0) |
Other/experimental products | 3 (0.6) |
Data prior to lymphodepletion | |
LDH (U/L) – median (IQR) | 256 (206–328) |
MCV (fl) – median (IQR) | 94 (89–98) |
Hemoglobin (g/dL) – median (IQR) | 10.7 (9.25–12.1) |
ANC (G/L) – median (IQR) | 2.10 (1.10–3.8) |
Platelet (G/L) – median (IQR) | 120 (52.0–200) |
ALC (G/L) – median (IQR) | 0.700 (0.47–1.05) |
CRP (mg/L) – median (IQR) | 6.00 (2.00–23.0) |
Ferritin (μg/L) – median (IQR) | 343 (155–827) |
CAR HEMATOTOX Score – median (IQR) | 2 (2–3) |
Median prior lines of therapy (IQR) | 2 (2–3) |
Prior autologous HCT, n (%) | 95 (17.6) |
Prior allogenic HCT, n (%) | 4 (0.7) |
Toxicity, n (%) | |
Any grade CRS n (%) | 467 (86.6) |
Severe CRS n (%) | 35 (6.5) |
Any grade ICANS n (%) | 191 (35.4) |
Severe ICANS n (%) | 48 (8.9) |
